dysgeusia/epuizare

Linkul este salvat în clipboard

Alegeți tipul de sortare

Pagină 1 din 81 rezultate

Acupuncture Therapy in Post-Radiation Head-and-Neck Cancer with Dysgeusia

Numai utilizatorii înregistrați pot traduce articole

Background: Radiation therapy for head-and-neck cancer can cause side-effects, including pain, nausea, vomiting, sensory disorders such as anosmia and dysgeusia, dysphagia, xerostomia, hot flashes, fatigue, sleep disorders, and even anxiety and depression disorders. Therapies using

Sunitinib in metastatic renal cell carcinoma (mRCC): a developing country experience. Do our patients behave differently than the Western patients?

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND Metastatic renal cell carcinoma (mRCC) has historically been refractory to cytotoxic and hormonal agents. IL-2 and IFN-α provide response in a minority of patients. Small molecule tyrosine kinase inhibitors and monoclonal antibodies have established a role in the setting of mRCC. However,

Clinical Characteristics of COVID-19 Patients With Gastrointestinal Symptoms in Northern Italy: A Single-Center Cohort Study

Numai utilizatorii înregistrați pot traduce articole

Introduction: The most typical presentation of COVID-19 is an acute respiratory syndrome whose most common symptoms include fever, cough, and dyspnea. However, gastrointestinal symptoms, such as diarrhea and nausea/vomiting, are

Diabetic Tongue - Could it be a Diagnostic Criterion?

Numai utilizatorii înregistrați pot traduce articole

Diabetes mellitus (DM) is a common disease which usually manifests in the form of polyuria, polydipsia, weight loss, fatigue, weakness, blurry vision, frequent skin infections, and slow healing of skin lesions. Taste disturbances like ageusia, hypogeusia and dysgeusia have been associated with DM.

Management of Adverse Events During Rucaparib Treatment for Relapsed Ovarian Cancer: A Review of Published Studies and Practical Guidance

Numai utilizatorii înregistrați pot traduce articole

The poly(ADP-ribose) polymerase inhibitor rucaparib is approved as monotherapy in the treatment and maintenance settings for women with relapsed ovarian cancer in the European Union and the United States. We review the safety profile of rucaparib in both settings and provide recommendations for the

Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND Quizartinib, an inhibitor of class III receptor tyrosine kinases (RTKs), is currently in phase 3 development for the treatment of acute myeloid leukemia (AML) bearing internal tandem duplications in the FLT3 gene. Aberrant RTK signaling is implicated in the pathogenesis of a variety of

Two different scenarios of advanced basal cell carcinomas during the use of vismodegib: Cases of oral administration and administration directly to the stomach.

Numai utilizatorii înregistrați pot traduce articole

No effective therapy exists for locally advanced or metastatic basal cell carcinoma (BCC). Vismodegib is a small molecule that is an inhibitor of the hedgehog pathway. An oral treatment to inactivate Smoothened would be a new therapeutic approach to treat advanced BCC. We studied two patients with

Evidence from a meta-analysis: is nivolumabneurotoxic in cancer patients?

Numai utilizatorii înregistrați pot traduce articole

The aim of this study was to summarize the findings of previous studies focusing on whether the risks of certain neurotoxicities are correlated to the programmed death 1 (PD-1) inhibitor nivolumab versus other chemotherapy or immunotherapy drugs. Six eligible studies, including 3,023 patients, were

A phase I pharmacological and biological study of PI-88 and docetaxel in patients with advanced malignancies.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE This study evaluated the safety, toxicity, pharmacological properties and biological activity of PI-88, a heparanase endoglycosidase enzyme inhibitor, with fixed weekly docetaxel in patients with advanced solid malignancies. METHODS This was a phase I study to determine the

Practical guide to supportive care of patients with functional neuroendocrine tumors.

Numai utilizatorii înregistrați pot traduce articole

Supportive care of patients with functional neuroendocrine tumors (NETs) has evolved to include the use of multiple targeted agents to control paraneoplastic states and newer surgical and interventional radiologic techniques to reduce tumor bulk. Challenges encountered by the clinician are the

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE Triple therapy with peginterferon/ribavirin (PR) plus an NS3 protease inhibitor has emerged as the standard-of-care for patients with chronic hepatitis C genotype-1. We provide a detailed safety analysis comparing PR to boceprevir plus PR (BOC/PR) across three phase 2/3

The effects of boceprevir and telaprevir on the pharmacokinetics of maraviroc: an open-label, fixed-sequence study in healthy volunteers.

Numai utilizatorii înregistrați pot traduce articole

OBJECTIVE To evaluate the effects of boceprevir (BOC) and telaprevir (TVR) on the pharmacokinetics (PK) of maraviroc (MVC) in healthy volunteers. METHODS In this open-label, fixed-sequence study, 14 volunteers received MVC 150 mg twice daily alone for 5 days (period 1), followed by MVC + BOC 800 mg

How to optimize HCV therapy in genotype 1 patients: management of side-effects.

Numai utilizatorii înregistrați pot traduce articole

Antiviral therapy for chronic hepatitis C has dramatically changed with the advent of triple therapy incorporating direct-acting antivirals (DAAs) such as the protease inhibitors (PI) boceprevir and telaprevir. Such triple-therapy is associated with a new spectrum of side-effects which can hamper

Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND Evidence on adjuvant chemotherapy in older women with breast cancer is poor. We tested whether weekly docetaxel is more effective than standard chemotherapy. METHODS We carried out a multicenter, randomized phase III study. Women aged 65-79, operated for breast cancer, with average to

Cholestatic hepatic injury associated with vismodegib, aspirin, and naproxen use: a case study and review of vismodegib safety.

Numai utilizatorii înregistrați pot traduce articole

BACKGROUND Vismodegib is a novel hedgehog pathway inhibitor approved to treat advanced and metastatic basal cell carcinoma (BCC) in the United States. Several studies have demonstrated efficacy for treatment of new and existing BCC in both basal cell nevus syndrome (BCNS) and non-BCNS patients.

Anterior
1
2
3
4
5
6
Următor →

Alăturați-vă paginii
noastre de facebook

Herbal & Natural Medicine

Cea mai completă bază de date cu plante medicinale susținută de știință

Funcționează în 55 de limbi
Cure pe bază de plante susținute de știință
Recunoașterea ierburilor după imagine
Harta GPS interactivă - etichetați ierburile în locație (în curând)
Citiți publicațiile științifice legate de căutarea dvs.
Căutați plante medicinale după efectele lor
Organizați-vă interesele și rămâneți la curent cu noutățile de cercetare, studiile clinice și brevetele

Tastați un simptom sau o boală și citiți despre plante care ar putea ajuta, tastați o plantă și vedeți boli și simptome împotriva cărora este folosit.
* Toate informațiile se bazează pe cercetări științifice publicate